{
    "2018-03-23": [
        [
            {
                "time": "2018-09-12",
                "original_text": "Pharma Stock Roundup: ABBV's Rova-T Disappoints, J&J Unit Gets Buyout Offer",
                "features": {
                    "keywords": [
                        "ABBV",
                        "Rova-T",
                        "Disappoints",
                        "J&J",
                        "Buyout Offer"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-13",
                "original_text": "Commentary: 5 Questions Facebook’s Leaders Still Need to Face",
                "features": {
                    "keywords": [
                        "Facebook",
                        "Leaders",
                        "Questions"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-14",
                "original_text": "Pfizer is having a tough time selling its consumer health care business",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "consumer health care",
                        "tough time"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-15",
                "original_text": "Why Geron Corp. Is Rallying 10% Today",
                "features": {
                    "keywords": [
                        "Geron Corp.",
                        "Rallying",
                        "10%"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-16",
                "original_text": "Dow 30 Stock Roundup: Nike Beats, J&J Gets $2.1B Offer for Diabetes Device Unit",
                "features": {
                    "keywords": [
                        "Nike",
                        "Beats",
                        "J&J",
                        "$2.1B Offer",
                        "Diabetes Device Unit"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "apparel"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-17",
                "original_text": "VT, JPM, JNJ, CSCO: ETF Inflow Alert",
                "features": {
                    "keywords": [
                        "ETF",
                        "Inflow Alert",
                        "JPM",
                        "JNJ",
                        "CSCO"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "financials",
                        "technology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-18",
                "original_text": "These 12 Drugs Launching In 2018 Are Headed For Blockbuster Status",
                "features": {
                    "keywords": [
                        "Drugs",
                        "Launching",
                        "Blockbuster Status"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-19",
                "original_text": "The Recent Bid for Johnson & Johnson’s LifeScan Unit",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "LifeScan Unit",
                        "Bid"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-20",
                "original_text": "Better Buy: Johnson & Johnson vs. Merck",
                "features": {
                    "keywords": [
                        "Johnson & Johnson",
                        "Merck",
                        "Better Buy"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-21",
                "original_text": "AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Stock Falls",
                        "Weak Lung Cancer Study"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-09-22",
                "original_text": "How Gilead Sciences’ Ranexa, AmBisome, Zydelig, and Vosevi Performed",
                "features": {
                    "keywords": [
                        "Gilead Sciences",
                        "Ranexa",
                        "AmBisome",
                        "Zydelig",
                        "Vosevi",
                        "Performed"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-23",
                "original_text": "See what the IHS Markit Score report has to say about Johnson & Johnson.",
                "features": {
                    "keywords": [
                        "IHS Markit Score",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-09-24",
                "original_text": "How Gilead’s Viread, Complera, and Letairis Performed",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Viread",
                        "Complera",
                        "Letairis",
                        "Performed"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-09-25",
                "original_text": "Inside J&J's Effort to Cut Costs and Drive Integration at Ad Firms WPP and Omnicom",
                "features": {
                    "keywords": [
                        "J&J",
                        "Cut Costs",
                        "Integration",
                        "WPP",
                        "Omnicom"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "advertising"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}